NCT04216121

LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib

Local AblativeTherapy for Oligoprogressive Non-Small-Cell Lung Cancer Treated With First-line OSImertinib

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 39 (estimated)
• Sponsor: Universitaire Ziekenhuizen KU Leuven · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To determine whether in patients with EGFR mutated advanced NSCLC and osimertinib as first-line treatment, the (repeated) use of LAT to ≤ 3 OP lesions and continuation of first-line osimertinib, improves the median progression-free survival by more than 3 months (i.e. PFS2-PFS1 = \>3 months).

Detailed description

The (repeated) use of LAT to ≤ 3 OP lesions with continuation of first-line osimertinib, is endorsed by international guidelines (NCCN, ESMO). In this phase IIb prospective non-randomized observational trial, we want to document the benefit of LAT in this patient cohort.

Conditions

• Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

Interventions

Type	Name	Description
RADIATION	Local ablative therapy	Stereotactic body radiotherapy
PROCEDURE	Local ablative therapy	Surgery

Timeline

• Start date: 2021-05-10
• Primary completion: 2025-10-01
• Completion: 2025-10-01
• First posted: 2020-01-02
• Last updated: 2024-07-01

Locations

1 site across 1 country: Belgium